SAN MATEO, CA--(MARKET WIRE)--Jun 27, 2007 -- SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) today announced it has initiated a proof-of-concept phase 2 clinical trial using its proprietary compound SCV-07 as a sole agent to treat patients infected with the hepatitis C virus (HCV). The trial is designed to evaluate the therapeutic effect of SCV-07 on patients with HCV.
